Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02538484 · ClinicalTrials.gov registry record · Early Phase 1

Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

A Early Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.

Completed
Registry status
Early Phase 1
Development phase
24
Enrollment target

NCT02538484 is a Early Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02538484, a Early Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.

COMPLETED
Registry status
Early Phase 1
Development phase
24 participants
Enrollment target

Study Summary

Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.

Interventions

  • DRUG Letrozole
  • DIETARY_SUPPLEMENT Fish Oil

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2016-04
Est. Completion 2020-03-26
Phase Early Phase 1

What the Registry Record Tells You About NCT02538484

The ClinicalTrials.gov registry entry for NCT02538484 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Letrozole is the first listed.

NCT02538484 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02538484 about?

NCT02538484 is a clinical study titled "Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects". Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.

What is the current status of trial NCT02538484?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2016-04. Estimated completion is 2020-03-26.

What interventions are being tested in trial NCT02538484?

The interventions under investigation include: Letrozole (DRUG), Fish Oil (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02538484?

This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.